TY - JOUR
AU - Rouvier, Philippe
AB - Monoclonal antibodies directed against the immune checkpoint protein cytotoxic T-lymphocyte antigen-4 (CTLA-4; CD152) have been investigated in metastatic melanoma and other cancers and have shown promising results. Inhibition of CTLA-4 characteristically induces well-known side effects called “immune-related adverse events” (irAEs). IrAEs mainly include colitis, dermatitis, hepatitis, endocrinopathies; uveitis, iridocyclitis, neuropathies, and inflammatory myopathy have occasionally been reported. Kidney involvement is rare. We report 2 cases of acute granulomatous interstitial nephritis and present, based on literature review, renal disorders related to Ipilimumab therapy. Autoimmune symptoms have to be carefully checked for patients treated with CTLA-4 inhibitors. In order to reduce the risk of sequelae, early recognition of irAEs and treatment initiation are crucial.
TI - Kidney injuries related to ipilimumab
JF - Investigational New Drugs
DO - 10.1007/s10637-014-0092-7
DA - 2014-04-01
UR - https://www.deepdyve.com/lp/springer-journals/kidney-injuries-related-to-ipilimumab-zL0dnjuKGB
SP - 769
EP - 773
VL - 32
IS - 4
DP - DeepDyve
ER -